Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Discovery and Transgenomic Collaborate

Published: Thursday, January 16, 2014
Last Updated: Thursday, January 16, 2014
Bookmark and Share
Collaboration agreement aims to develop improved genetic diagnostic tests incorporating state of the art controls.

The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon’s Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in future.

Under the terms of the agreement, Horizon will provide its renewable, genetically defined Quantitative Molecular Reference Standards in both gDNA (genomic DNA) and FFPE (formalin fixed paraffin embedded) format, via its Horizon Diagnostics division. The Quantitative Molecular Reference Standards will be used as advanced reference standards for Transgenomic’s range of genetic diagnostic tests, and in the development of novel tests and in vitro diagnostic testing kits. The Quantitative Molecular Reference Standard products will be chosen from Horizon Diagnostics’ existing inventory of over 300 products, and Horizon’s GENESIS™ gene editing platform will also be employed to precisely engineer new lines as needed, to support the development of the new tests and kits. 

“Combining Horizon’s technology for developing reliable, genetically defined Quantitative Molecular Reference Standards, with Transgenomic’s expertise in molecular diagnostic technologies, this collaboration provides strategic opportunities that will significantly benefit our biomarker identification business,” said Paul Kinnon, President and Chief Executive Officer of Transgenomic.  “We are excited to be working with Horizon, a leader in the personalized medicine field, as we work to expand our test and kit offerings in the rapidly growing area of companion diagnostics.”

“Transgenomic operates at the cutting edge of molecular diagnostics and is an ideal partner for Horizon,” said Paul Morrill, Senior Vice President of Horizon Diagnostics.  “This collaboration adds to our strong network of world class partners practicing high quality science, and contributes to our goal of advancing personalized medicine and ultimately better patient care.  We look forward to working with the Transgenomic team.”

Horizon Diagnostics’ Reference Standard product portfolio comprises highly validated, engineered cell line derived material, including purified DNA with matched normal and renewable formalin fixed, paraffin embedded samples. The available specimens cover a growing range of oncology biomarkers, manufactured to precise standards including defined allelic frequencies.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CareDx and Horizon Enter into a Collaboration
Horizon’s standards to support proficiency testing of CareDx solid organ transplantation injury monitoring diagnostic assay.
Thursday, June 04, 2015
Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
Grahame brings over 20 years’ experience to Horizon.
Thursday, May 14, 2015
Transgenomic to Incorporate Horizon's Genomic Reference Standards
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits.
Thursday, April 23, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon Discovery Group plc Trading Update
Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering.
Monday, January 19, 2015
Horizon Discovery Group plc Establishes Scientific Advisory Board for Horizon Diagnostics Business Unit
The Scientific Advisory Board will recommend improvements needed in laboratories adopting Companion Diagnostic assays.
Tuesday, November 11, 2014
Horizon Signs Master Services Agreement for Approximately $1.2 Million
Agreement covers development of molecular reference standards for companion diagnostics.
Friday, September 26, 2014
Horizon Reports a Strong First Half
Interim results for the six months ended 30 June 2014 position the company for continued growth.
Tuesday, September 23, 2014
Horizon, LGC Awarded Technology Strategy Board Grant
Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies.
Tuesday, June 17, 2014
Horizon Discovery and Desktop Genetics Collaborate on CRISPR Design Platform
Platform to be used as part of Horizon’s GENESIS suite of gene editing technologies.
Tuesday, December 17, 2013
Horizon Strengthens Board with Appointment of Dr. Ian Gilham
Appointment of Dr. Ian Gilham as non-executive director.
Friday, August 02, 2013
Horizon Discovery and Diatech Pharmacogenetics Sign Distribution Agreement
Agreement covers distribution of Horizon Diagnostics’ molecular reference standards products in Italy, San Marino and Vatican City.
Monday, April 15, 2013
Horizon Receives the Queen’s Award for Enterprise in International Trade
The UK’s most prestigious business award granted in recognition of outstanding achievement in export growth.
Monday, April 23, 2012
UK Translational Genomics Company Horizon Discovery Launches new Companion Diagnostics Venture
New venture will support the development, approval and sale of companion diagnostic products in the field of cancer.
Thursday, January 07, 2010
Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!